NeuroSense Therapeutics
milestones achieved upcoming potential catalysts | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
22 of 34
Similar slides by NeuroSense Therapeutics
See diffirences between slides (animation)
Investor Presentation
January 2024
milestones achieved and upcoming potential catalysts | NeuroSense Therapeutics
Investor Presentation
December 2023
milestones achieved and upcoming potential catalysts | NeuroSense Therapeutics
Related slides by other companies
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase sad mad trial initiated in trial design randomized double blind trial population healthy subjects sad mad primary objectives assess the safety tolerability of sad and mad of evaluate the profile of after single and multiple doses trial update enrollment is progressing in several sad cohorts and at least one cohort has been extremely safe and well tolerated complete safety and data expected study underway | Recursion Pharmaceuticals
Arbutus Biopharma
Investor Presentation
May 2023
next generation oral | Arbutus Biopharma
MindMed
Investor Presentation
April 2021
develop phase a clinical trial | MindMed
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
October 2024
Investor Presentation
January 2024
Investor Presentation
December 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights